PBMS-IMRT对降低同步放化疗盆腔肿瘤患者血液不良反应研究的新进展

对晚期盆腔肿瘤患者采用同步放化疗可以提高其生存率,但血液等不良反应明显增多,常导致患者不能耐受而中断治疗。限定盆骨骨髓调强放疗(PBMS-IMRT)在降低盆骨骨髓照射剂量和体积方面具有明显优势,本文就PBMS-IMRT与其他照射方式的比较、放疗剂量学参数与血液不良反应的相关性以及勾画精确活性骨髓的影像学方法进行综述。

Research progress in effect of pelvic bone marrow-sparing intensity-modulated radiotherapy on hematologic toxicity in pelvic tumor patients after concurrent chemoradiotherapy

oncurrent chemoradiotherapy can improve the survival rate in patients with advanced pelvic tumors. However, it also increases the incidence of hematologic toxicity and other adverse events. Patients cannot tolerate these adverse events and discontinue the therapy. Pelvic bone marrow-sparing intensity-modulated radiotherapy (PBMS-IMRT) possesses obvious advantages in reducing the radiation dose and volume of the pelvic bone marrow. In this article, comparison between PBMS-IMRT and other irradiation therapies, correlation between dosimetric parameters and hematologic toxicity and imaging Methods with precise delineation of the active bone marrow were reviewed.